1. Home
  2. FSHP vs KPTI Comparison

FSHP vs KPTI Comparison

Compare FSHP & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSHP
  • KPTI
  • Stock Information
  • Founded
  • FSHP 2018
  • KPTI 2008
  • Country
  • FSHP United States
  • KPTI United States
  • Employees
  • FSHP N/A
  • KPTI N/A
  • Industry
  • FSHP
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • FSHP
  • KPTI Health Care
  • Exchange
  • FSHP NYSE
  • KPTI Nasdaq
  • Market Cap
  • FSHP 90.7M
  • KPTI 81.1M
  • IPO Year
  • FSHP 2024
  • KPTI 2013
  • Fundamental
  • Price
  • FSHP $10.23
  • KPTI $0.62
  • Analyst Decision
  • FSHP
  • KPTI Strong Buy
  • Analyst Count
  • FSHP 0
  • KPTI 4
  • Target Price
  • FSHP N/A
  • KPTI $5.00
  • AVG Volume (30 Days)
  • FSHP 7.5K
  • KPTI 768.4K
  • Earning Date
  • FSHP 01-01-0001
  • KPTI 02-19-2025
  • Dividend Yield
  • FSHP N/A
  • KPTI N/A
  • EPS Growth
  • FSHP N/A
  • KPTI N/A
  • EPS
  • FSHP 0.11
  • KPTI N/A
  • Revenue
  • FSHP N/A
  • KPTI $148,442,000.00
  • Revenue This Year
  • FSHP N/A
  • KPTI $4.47
  • Revenue Next Year
  • FSHP N/A
  • KPTI $7.35
  • P/E Ratio
  • FSHP $90.07
  • KPTI N/A
  • Revenue Growth
  • FSHP N/A
  • KPTI 1.77
  • 52 Week Low
  • FSHP $9.99
  • KPTI $0.58
  • 52 Week High
  • FSHP $10.25
  • KPTI $1.70
  • Technical
  • Relative Strength Index (RSI)
  • FSHP N/A
  • KPTI 43.29
  • Support Level
  • FSHP N/A
  • KPTI $0.58
  • Resistance Level
  • FSHP N/A
  • KPTI $0.67
  • Average True Range (ATR)
  • FSHP 0.00
  • KPTI 0.05
  • MACD
  • FSHP 0.00
  • KPTI -0.00
  • Stochastic Oscillator
  • FSHP 0.00
  • KPTI 31.02

About FSHP FLAG SHIP ACQUISITION CORPORATION

Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: